The FDA accepted Ortho Dermatologics’ resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of February 15, 2019. “We are confident in our NDA resubmission for Duobrii and unwavering in our commitment…
Salix Expands Microbiome Research And Discovery Through Collaboration With Cedars-Sinai Medical Center
Salix Pharmaceuticals, a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders and a wholly owned subsidiary of Bausch Health Companies Inc. announced its affiliate has entered into a research agreement with Cedars-Sinai Medical Center to further investigate the microbiome in the treatment of GI disorders. Under the terms of the…